A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered as a Single Agent or in Combination with other Anti-Cancer Therapies in Patients Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505102-42-00

Acronym

MO29406

Enrollment

Registered

2024-06-17

Start date

2014-12-18

Completion date

Unknown

Last updated

2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Malignant Tumors

Brief summary

AEs, serious adverse events (SAEs), AEs leading to pertuzumab discontinuation or dose interruption, and non-serious AEs of special interest (AESIs) Adverse events will be classified according to the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE]

Detailed description

1. Assessments of Progression free survival (PFS) will be done per Investigator’s assessment, based on local institution’s standard of care, 2. Overall Survival (OS)

Interventions

DRUGPerjeta 420 mg concentrate for solution for infusion

DRUGHerceptin 150 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
AEs, serious adverse events (SAEs), AEs leading to pertuzumab discontinuation or dose interruption, and non-serious AEs of special interest (AESIs) Adverse events will be classified according to the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE]	—

Secondary

Measure	Time frame
1. Assessments of Progression free survival (PFS) will be done per Investigator’s assessment, based on local institution’s standard of care, 2. Overall Survival (OS)	—

Countries

Italy, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026